Nefazodone hydrochloride (Serzone®) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone® in the United States. Several generic formulations of nefazodone are still available.Orange Book, accessed 15 January 2006."Serzone Pulled from U.S. Market", accessed 15 January 2006.
Nefazodone is most closely related to Desyrel® (trazodone). Nefazodone is not considered to be an SSRI, MAOI or tricyclic antidepressant. It is not chemically related to either bupropion/amfebutamone or Effexor® (venlafaxine).
More on [ Nefazodone ]
Antidepressants :: Drugs and Medications

DrugDigest: Nefazodone (Serzone) - Information on dosage, usage, side effects, interactions, and comparisons with other antidepressant medications.
MedlinePlus: Nefazodone (Serzone) - Patient's guide provided by the United States Pharmacopeia.
Meta Description: [ Nefazodone (Systemic) ]
The Toronto Star - Canada Pulls Anti-depressant Off Shelves - Short news article describes government action in reaction to reports of serious liver damage from nefazodone.
| New Warnings on Suicidality in Young Adults Taking Antidepre | |